Page 230 - HIV/AIDS Guidelines

Appendix B, Table 2. Characteristics of Non-Nucleoside Reverse Transcriptase Inhibitors* (NNRTIs)
(Last updated October 14, 2011; last reviewed March 27, 2012) (page 2 of 2)

*DLV is not included in this table. Please refer to the DLV FDA package insert for related information.

Dosing
Recommendations
Generic Name
Adverse Events
Serum/
(abbreviation)/ Formulations (For dosage adjustment Elimination Half-life (Also see Table 13)
in renal or hepatic
Trade Name
insufficiency, see
Appendix B, Table 7.)
Rilpivirine (RPV)/ • 25-mg tablet 25 mg once daily CYP3A4 50 hrs • Rash a
Edurant substrate
Take with a meal. • Depression, insomnia, headache
Also available as
component of
fixed-dose
combination:
Complera Complera 1 tablet once daily with a
RPV with TDF + (RPV 25 mg + meal
FTC TDF 300 mg +
FTC 200 mg) tablet

Key to Abbreviations: ARV = antiretroviral, BID = twice daily, CYP = cytochrome P, DLV = delavirdine, EFV = efavirenz, ETR = etravirine,
FDA = Food and Drug Administration, FTC = emtricitabine, HSR = hypersensitivity reaction, NNRTI = non-nucleoside reverse transcriptase inhibitor,
NVP = nevirapine, RPV = rilpivirine, TDF = tenofovir disoproxil fumarate, XR = extended release
a
Rare cases of Stevens-Johnson syndrome have been reported with most NNRTIs; the highest incidence of rash was seen with NVP.
b
Adverse events can include dizziness, somnolence, insomnia, abnormal dreams, confusion, abnormal thinking, impaired concentration, amnesia,
agitation, depersonalization, hallucinations, and euphoria. Approximately 50% of patients receiving EFV may experience any of these symptoms.
Symptoms usually subside spontaneously after 2 to 4 weeks but may necessitate discontinuation of EFV in a small percentage of patients.

Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents O-5

Downloaded from http://aidsinfo.nih.gov/guidelines on 12/8/2012 EST.